ADAC Announces VANTAGE Clinical Trial Results.

MILPITAS, Calif.--(BUSINESS WIRE)--June 4, 1996--ADAC Laboratories (NASDAQ:ADAC) announced today that preliminary results from a multi-center trial for the Company's VANTAGE(TM) non-uniform attenuation correction were presented at the annual Society of Nuclear Medicine (SNM) meeting held this week in Denver, Colorado.

The results demonstrate that VANTAGE provides physicians with the improved image quality required to achieve greater clinical efficiency, diagnosis accuracy and physician confidence. The diagnostic benefits of VANTAGE are discussed in seven abstracts presented at the SNM meeting.

VANTAGE is designed to improve the accuracy in the detection of cardiac disease by correcting image distortions created by the non-uniform variations of tissue density in the body. The use of VANTAGE is expected to improve the clinical accuracy of cardiac diagnosis and improve the cost effectiveness in cardiac patient management.

Dr. Robert Hendel, Co-Director of Nuclear Cardiology, Northwestern University Hospital and Assistant Professor of Medicine at Northwestern University Medical School, Chicago, stated, "The multi-center investigation of VANTAGE included over 300 patients at 6 sites. The preliminary results, thus far, suggest a significant improvement in normalcy rate, or diagnostic specificity, using VANTAGE. These affects are primarily noted in patients suspected of diaphragmatic attenuation. Therefore, the use of VANTAGE may result in a significant reduction in false positive profusion studies in patients that lack evidence of coronary disease."

Dr. Daniel Berman, Director of Nuclear Cardiology, Cedars Sinai Medical Center and Professor of Medicine, UCLA School of Medicine, Los Angeles, stated, "We use VANTAGE as a routine patient study and find that it is a useful addition to myocardial profusion SPECT. VANTAGE provides physicians with the ability to simultaneously look at uncorrected and corrected images. The directional change that VANTAGE displays enables us to detect attenuation artifacts and thereby increase diagnostic confidence and eliminate the need to perform additional acquisition procedures. In the future, attenuation correction capability may pave the way to absolute quantification of myocardial tracer uptake, potentially leading to a dramatic improvement of assessing the viability of the myocardial and the extent of coronary artery disease."

ADAC also announced a joint development agreement with Emory University to develop future generations of VANTAGE enhancements.

ADAC Laboratories is the world market share leader in nuclear medicine and a leading supplier of radiology and laboratory information systems in North America. For the second consecutive year, ADAC has received a site visit for the prestigious Malcolm Baldrige National Quality Award. The Company headquarters is in Milpitas, California.

CONTACT: ADAC Laboratories

Kathleen Call, 408/321-9100